Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) EBIT (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed EBIT for 4 consecutive years, with -$68.5 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 8.19% to -$68.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$207.7 million through Dec 2025, down 3.3% year-over-year, with the annual reading at -$207.7 million for FY2025, 3.3% down from the prior year.
  • EBIT for Q4 2025 was -$68.5 million at Centessa Pharmaceuticals, down from -$53.8 million in the prior quarter.
  • The five-year high for EBIT was -$30.8 million in Q1 2025, with the low at -$74.6 million in Q4 2024.
  • Average EBIT over 4 years is -$49.5 million, with a median of -$47.9 million recorded in 2023.
  • The sharpest move saw EBIT soared 31.27% in 2023, then crashed 112.01% in 2024.
  • Over 4 years, EBIT stood at -$41.6 million in 2022, then rose by 15.44% to -$35.2 million in 2023, then tumbled by 112.01% to -$74.6 million in 2024, then increased by 8.19% to -$68.5 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$68.5 million, -$53.8 million, and -$54.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.